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their cysteines next to each other (CC) or being separated 
by a single amino acid (CXC). Chemokines function via 
7 transmembrane-spanning G protein-coupled receptors 
which signal upon chemokine binding. Traditional che-
mokine receptors bind ligands of a single subgroup, and 
they are defined accordingly (CCRs, CXCRs, CX3CR1, 
XCR1). Activation of chemokine receptors typically trig-
gers phospholipase C activation via the   -subunits (re-
leased from G  i) resulting in calcium mobilization  [2, 3] .
 As inflammatory cells migrate from the bloodstream, 
a chemokine signal is necessary for firm adhesion to the 
endothelium of venules. Therefore, chemokines need ei-
ther to be expressed by endothelial cells, deposited on en-
dothelial surfaces by platelets, or be transported through 
the endothelial layer, to be presented to passing leuko-
cytes  [4] . Having left the vessels, inflammatory cells trav-
el through interstitial tissues most likely following hap-
totactic (matrix-bound) gradients towards the site of in-
jury  [3] . Defined structures of the extracellular matrix, 
particularly glycosaminoglycans and nonsignaling che-
mokine-binding proteins, are sites of chemokine presen-
tation, and in the case of the interceptors, also transport 
 [5] . These presenting structures change during inflam-
mation  [6] . Additionally, chemokine function is modified 
by the formation of dimers and multimers, occurring in 
the ligands and receptors  [3] .
 An additional cascade of interactions between chemo-
kines, soluble mediators, adhesion molecules and chemo-
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 Abstract
 Chemokines are structurally related proteins which form a 
large family of chemotactic cytokines. They provide a gen-
eral communication system for cells and regulate lympho-
cyte migration. These proteins orchestrate the formation of 
microenvironments in lymphoid tissue, promote lymphoid 
organogenesis and help foster vascular and lymphatic an-
giogenesis. In addition to the classical G protein-coupled 
chemokine receptors, many chemokines also bind to a fam-
ily of nonsignaling proteins, now called interceptors (chemo-
kine-internalizing proteins). Here we summarize recent data 
on the role of interceptors in chemokine biology with a focus 
on renal inflammation.  Copyright © 2010 S. Karger AG, Basel
 Introduction
 Chemokines are members of a family of chemotactic 
factors, defined by a conserved motif of cysteine residues 
 [1, 2] . The position of the 2 N-terminal cysteines defines 
4 chemokine subgroups, with the 2 large groups having 
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kine receptors are involved when cells exit the inflamed 
organ. Inflammatory cells (e.g. lymphocytes, dendritic 
cells) exit tissues through the lymphatic vessels. The role 
of the lymphatics, and particularly the lymphatic endo-
thelial cells in this process, is a developing area of re-
search. In the last 2 years, excellent reviews have summa-
rized many aspects of the current literature on the role of 
chemokines in renal diseases  [7–11] . In this brief review, 
we will discuss the family of nonsignaling receptors, 
called interceptors or atypical receptors, which have re-
cently been shown to modify chemokine functions  [12] .
 Interceptors, Nonsignaling or Atypical Chemokine 
Receptors
 The atypical chemokine receptors are a family of 7 
transmembrane-spanning proteins, which bind chemo-
kines but do not signal via the typical G protein-mediat-
ed pathways  [13–15] . This is thought to be due to the lack 
of the typical conserved sequence, the DRYLAIV motif, 
which is usually present on the second intracellular loop 
and normally enables G protein coupling  [16] . Currently, 
members of this family include the Duffy antigen/recep-
tor for chemokines (DARC), the protein D6 and the Che-
mocentryx chemokine receptor (CCX-CKR  [12, 15] ). In 
addition, the receptor CXCR7, which does not appear to 
signal via the classical pathways, has been provisionally 
associated with the interceptors.
 As compared to chemokine receptors, the interceptors 
usually show a broader binding spectrum of chemokines, 
even binding ligands of different subgroups ( table  1 ). 
Multiple functions for interceptors have been proposed 
which appear to depend in part on the particular micro-
environment studied. The following functions have been 
suggested and/or documented under specific conditions. 
(1) Interceptors are thought to compete with typical re-
ceptors by acting as scavengers (e.g. DARC expressed on 
red blood cells). (2) Binding of chemokines at a site of high 
concentration and the release at lower concentrations 
might increase the half-life in the circulation (‘slow re-
lease substance’). (3) Interceptors appear to bind and in-
ternalize chemokines leading to their degradation (as 
demonstrated for D6). (4) Chemokines can be shuttled 
through cells and presented on the other side of the cells 
(as illustrated for DARC  [17] ). This decreases the concen-
tration on one side of the cell, but increases it on the oth-
er side (e.g. the endothelial surface). (5) Interceptors have 
been proposed to act as potential presentation structures 
on the endothelial surface. (6) Interaction between typi-
cal and atypical receptors may help moderate the re-
sponse of the typical receptor to the corresponding ligand 
(as demonstrated for CXCR7).
 DARC in Renal Inflammation
 DARC binds 11 inflammatory chemokines of the CC 
and CXC groups ( table 1 ) with a high affinity, but does 
not bind noninflammatory chemokines  [18, 19] . This 
protein was initially identified as the Duffy red blood 
group antigen. As such it can be involved in transfusion 
reactions, and it mediates invasion of red blood cells by 
malaria parasites  [4, 20, 21] . In addition to red blood cells, 
DARC is also expressed on a subset of endothelial cells, 
particularly the high endothelial venules in lymphoid tis-
sue, venules of the skin, and peritubular capillaries in the 
kidney  [22–27] . DARC has also been described on some 
regions of lymphatic vessels, the so-called pre-collectors 
 [28] . In this regard, DARC appears to be expressed on 
blood endothelium at the sites of recirculation and ex-
travasation of inflammatory cells  [23–25, 27] .
 Table 1. ‘Nonsignaling’ chemokine-binding proteins
 Interceptor  Ligands (homeostatic)  Ligands (inflammatory)  Site of expression 
 DARC  CCL2, CCL5, CCL7, CCL11,
 CCL13, CCL14, CCL17, CXCL5,
 CXCL6, CXCL8, CXCL11 [17] 
 red blood cells, blood endothelium (high endothe-
lial venules, peritubular capillaries in the kidney), 
some lymphatic endothelial cells 
 D6  CCL2, CCL3 CCL4, CCL5, CCL7,
 CCL8, CCL11, CCL13, CCL14, 
 lymphatic endothelial cells 
 CCX-CKR  CCL19, CCL21, CCL25  bronchial alveolar cells 
 CXCR7  CXCL12  CXCL11  blood and lymphatic endothelial cells, lymphocytes 
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 DARC has also been proposed to modulate the chemo-
kine milieu at the lymphatic ‘exit site’  [28] . During renal 
inflammation, for example, in human crescentic glomer-
ulonephritis as well as in all forms of allograft rejection 
(interstitial, vascular and humoral), the number of in-
terstitial DARC-positive vessels have been shown to in-
crease  [23, 24] . We recently demonstrated that DARC on 
endothelial cells internalized chemokines on the basal 
side and mediated chemokine transcytosis  [17] . This re-
sulted in apical retention of intact chemokines and in-
creased leukocyte migration across monolayers express-
ing DARC  [17] . Mice overexpressing DARC on blood ves-
sel endothelium displayed enhanced chemokine-induced 
leukocyte extravasation and contact hypersensitivity re-
action  [17] . The restricted expression of DARC in the tu-
bulointerstitium, and the positive association with CCR5-
positive T cells in the corresponding compartment, also 
suggested a role for transcytosis/presentation by DARC 
on specific endothelial cells in the human kidney  [29] .
 Darc -deficient mice have been used in 2 studies to bet-
ter characterize the potential function of DARC in renal 
inflammation. In neutrophil-mediated mouse models 
(lipopolysaccharide injection and ischemia-reperfusion 
injury), deficiency of DARC resulted in a significant re-
duction in leukocyte recruitment and improved mor-
phology. In particular, the neutrophil recruitment to the 
post-ischemic kidney was significantly reduced in  Darc-
 deficient mice  [30] . We performed unilateral ureteral li-
gation and nephrotoxic serum nephritis studies in the 
 Darc -deficient mice  [31] . In both models, while an early 
increase in T cell recruitment was seen, at later time 
points, the chronic lesions and functional data were not 
different between the  Darc -deficient and wild-type mice 
 [31] . This suggests that while preserved recruitment of 
leukocytes is seen in chronic disease models in the ab-
sence of endothelial DARC, in acute neutrophil-depen-
dent models, the injury process was ameliorated. Unfor-
tunately, the overall interpretation is still difficult be-
cause of the complex functional consequences of DARC 
deficiency both on endothelial cells and erythrocytes. 
Depending on the microenvironment studied, the ab-
sence of DARC may have pro- or even anti-inflammatory 
effects. These questions will await experiments in which 
mice with selective cell-specific DARC deficiency can be 
used (deficiency on red blood cells versus endothelial 
cells).
 CXCR7 – A New Partner for Two Well-Known 
Chemokines
 For a long time, the CXCR4 receptor was thought to be 
the only binding site for the ligand CXCL12. The orphan 
receptor RDC1 was first cloned based on its homology 
with the conserved domain of G protein-coupled recep-
tors. In addition, the gene was localized to chromosome 
2, close to other CXC chemokine receptors  [32, 33] . It was 
renamed CXCR7 recently, when it was found to bind the 
chemokines CXCL12 and CXCL11 with high affinity  [34, 
35] . Mice deficient in either CXCR4 or CXCL12 both 
show a similar embryonic lethal phenotype  [36–38] . 
These include severe defects in lymphopoiesis, and neu-
ronal and heart development  [37, 38] . The binding of
radiolabeled CXCL12/SDF-1 to embryonic liver cells of 
CXCR4-deficient mice led to the description of a second 
receptor, now called CXCR7  [34] .
 A developmental role of CXCR7 has been demonstrat-
ed  [39–43] . In mice with a CXCR7 reporter knockin, 
CXCR7 was localized to cardiomyocytes, vascular endo-
thelial cells of lung and heart, the cerebral cortex and in 
osteocytes  [44] . The majority of CXCR7-deficient mice 
died within the first week after birth due to cardiovascu-
 Table 2. Functional roles of CXCR7
 CXCR7 and CXCR4 on the same cell  CXCR7 and CXCR4 on different cells 
 Scavenging of chemokines  Scavenging of chemokines 
 Reducing the availability for CXCR4  Reducing availability CXCL11 and CXCL12 for cells 
 Forma tion of heterodimers  Sharpening gradients and allowing migration to particular 
 Reduction in response to CXCL12 due to change in
 special orientation between CXCR4 and G  i1 
 microenvironments 
 Increasing calcium flux due to CXCL12, modifying
 signal transduction [32] 
 Sequestration of   -arrestin-2 away from CXCR4  Increased adhesion of T cells 
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lar malformations (ventricular septal defects and semilu-
nar heart valve malformation) with myocardial degen-
eration and fibrosis  [44, 45] . In a conditional knockout 
where CXCR7 was deleted on endothelial cells, this phe-
notype was recapitulated  [45] . The migration of CXCR4-
positive primordial germ cells was dependent on the ex-
pression of CXCR7-positive somatic cells in zebrafish 
 [41] . The knockdown of CXCR7 resulted in misguidance 
of the primordial germ cells  [41, 42] . This has an impor-
tant implication, as the scavenging of chemokines by
CXCR7-positive cells was necessary to localize CXCR4 to 
particular microenvironments. For this process to occur, 
CXCR7 and CXCR4 apparently need to be expressed on 
different cells, for example, CXCR7 expression on endo-
thelial cells.
 CXCR7 is an ‘atypical’ chemokine receptor, as binding 
of chemokines does not result in mobilization of intracel-
lular calcium, nor does it provoke direct chemotaxis of 
CXCR7-positive cells  [35, 46] . On the other hand, CXCR7 
does appear to be involved in a variety of physiological 
and pathological processes including the recruitment of 
stem cells  [47] , modulation of CXCL12-induced migra-
tion  [35] , internalization of the receptor after chemokine 
exposure  [35] , and tumor formation  [34, 48] . A role for 
CXCR7 in the transendothelial migration of tumor cells 
was recently defined  [49] . Ligand binding to CXCR7
led to the recruitment of   -arrestin2. Either CXCL11 or 
the small molecule CXCR7 ligand was found to block
the transendothelial migration of tumor cells (which 
were CXCR4 and CXCR7 double positive). Inhibition of
CXCL12-induced migration by the small molecule 
CXCR7 ligand was even more pronounced than that seen 
with a CXCR4 antagonist. Renal stem cells have also been 
shown to be CXCR4 and CXCR7 positive  [47] . Blocking 
either CXCR4 or CXCR7 was found to reduce their en-
graftment in acute renal failure  [47] . Transendothelial 
migration of these stem cells also required the presence 
of both receptors. CXCR7 was found to be essential for 
cell adhesion to endothelial cells  [47] .
 Interestingly, heterodimers form between CXCR7 and 
CXCR4, which can impair CXCL12-mediated responses 
in primary lymphocytes  [50] . This is most likely due to 
stabilization of the conformational state.
 The induction of the chemokine CXCL8/IL-8 has been 
demonstrated in prostate carcinoma cells via CXCR7 
 [51] . If this can be confirmed in other cell types, it may 
represent an important mechanism how CXCR7 ex-
pressed on endothelial cells can help promote the activa-
tion of a proinflammatory phenotype. The proposed 
functions of CXCR7 are summarized in  table 1 .
 The expression of CXCR7 on inflammatory cells like 
monocytes, B cells, and dendritic cells is still somewhat 
controversial  [52, 53] . The chemotaxis of T cells towards 
CXCL12 can be blocked by an anti-CXCR7 antibody  [34, 
35] . In gene chip analysis of human immune cells, the ex-
pression of CXCR7 was demonstrated on B cells, some T 
cell subsets and NK cells  [45] . CXCR7 deficiency has only 
a marginal effect on B cell development in mice  [45] . Be-
cause even relatively low levels of expression of CXCR7 
on lymphocytes could have a major impact on the local 
inflammatory milieu, the controversy may be due in part 
to the specific model systems used and the sensitivity of 
the antibodies used.
 Relatively little is known about the expression of 
CXCR7 in human tissues, particularly under pathologi-
cal conditions. CXCR7 was described on blood endothe-
lial cells and was found to be upregulated on human um-
bilical vein endothelial cells after stimulation with pro-
inflammatory cytokines  [34] . The most prominent cell 
adhesion was found when CXCR4 and CXCR7 were both 
expressed on the adhering leukocyte, and CXCR7 was 
expressed by the endothelial cells  [34] . The induction of 
CXCR7 was described on endothelial cells after they had 
been transformed by Kaposi’s sarcoma-associated her-
pesvirus  [54] . The proliferation of these cells could be 
prevented via blockade of CXCR7 by antisense molecules 
 [55] . Malignant brain tumors were also found to contain 
CXCR7-positive vessels  [56] . While an important role has 
been demonstrated for CXCL12 and CXCR4 in renal vas-
culature biology, a role for CXCR7 has not yet been de-
scribed  [57, 58] . While the effects can be demonstrated in 
animal models, the molecular role of endothelial CXCR7 
expression is still unclear.
 The increased expression of both CXCR7 ligands have 
been described in animal models of renal allograft rejec-
tion  [59–63] . We investigated the expression of CXCR7 in 
human renal allograft injury. CXCR7 and its correspond-
ing ligands were quantified at the mRNA level using 
quantitative PCR and the protein localized in renal al-
lograft biopsies  [64] . CXCL12 and CXCL11 mRNA were 
significantly induced in biopsies with borderline lesions 
and with acute allograft rejection  [64] . Expression of 
CXCR7 mRNA was also documented.
 CXCR7 protein was localized in 64 renal biopsies in-
cluding samples with acute rejection, chronic allograft 
injury, normal pretransplant biopsies as well as in a series 
of protocol biopsies  [64] . CXCR7 was found to be ex-
pressed on rare peritubular vessels, but not on glomerular 
endothelial cells in pretransplant controls. The number 
of CXCR7-positive peritubular vessels increased signifi-
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cantly in biopsies with acute interstitial and acute vascu-
lar rejection. Double staining with the lymphatic marker 
podoplanin demonstrated that a subset of CXCR7-pos-
itive vessels was identified as lymphatic vessels  [64] .
CXCR7-positive blood and lymphatic vessels increased 
during allograft rejection.
 Thus, in human renal allografts, CXCR7 is situated at 
2 strategic sites (peritubular capillaries and lymphatic 
vessel) at which the inflammatory cell influx and the ef-
flux from the allograft is regulated. Further studies are 
necessary to define the functional role of CXCR7 on en-
dothelial cells. Unfortunately, CXCR7-deficient mice die 
shortly after birth due to heart defects, therefore, induc-
ible knockout animals and antagonist studies will have to 
be used to define the functional role of CXCR7 in renal 
allograft injury  [44, 45] .
 D6 Is a Chemokine Scavenger
 D6 binds multiple proinflammatory CC chemokines 
( table 1 )  [65] . D6 is localized to endothelial cells of lym-
phatic vessels in the skin  [66] . In contrast to DARC, which 
appears to shuttle and present chemokines, D6 is thought 
to primarily act as a chemokine scavenger  [17, 67] . The 
chemokines that bind D6 are rapidly internalized and de-
graded, while D6 is recycled to the cell surface  [68] . D6-
mediated chemokine internalization occurs without sig-
nificant surface reduction of D6 due to internalization
in recycling endosomes  [68] . D6-deficient mice demon-
strate exacerbated responses in skin inflammation and 
increased cell numbers in draining lymph nodes  [69] . Re-
cently, interest has focused on the potential role of D6 on 
leukocytes where it may help balance the inflammatory 
response which is necessary for repair following inflam-
matory tissue injury  [67] .
 CCX-CKR – A New Kid on the Block
 In contrast to D6 and DARC, CCX-CKR binds ho-
meostatic chemokines including CCL19, CCL21, and 
CCL25  [70] . CCL21 is thought to play a role in renal in-
flammation  [71, 72] . CCX-CKR sufficiently scavenges 
CCL19, which leads to intracellular degradation  [73] . Ex-
pression of CCX-CKR was found predominantly in heart 
and lungs and was localized to bronchial epithelial cells 
in the lung  [74] . To date, CCX-CKR has not been studied 
in the kidney.
 General Functions of ‘Nonsignaling’ Receptors
 The atypical chemokine receptors add another level of 
complexity to the chemokine system. Many studies of the 
biologic roles of these proteins using classical knockout 
animals have not shown a phenotype which suggests a 
redundant mode of action. Importantly, nature has 
evolved a red blood cell-specific human ‘knockout’ of 
DARC in areas of endemic malaria. This suggests an evo-
lutionary pressure to conserve the endothelial DARC ex-
pression. Generally, both classical as well as nonsignaling 
chemokine receptors can bind and internalize chemo-
kines. The net result for the inflammatory process ap-
pears to depend on the local microenvironment. A new 
concept is highlighted by the role of CXCR7 during de-
velopment. In this context, the scavenging action of the 
receptor is thought to help focus chemokine gradients ne-
cessitating its localization in specific microenviron-
ments. If the same mechanism would be true for mam-
malian cells, the expression of atypical receptors on en-
dothelial cells might be involved in the recruitment of 
inflammatory cells via the formation of defined chemo-
kine gradients.
 Conclusions
 The family of nonsignaling chemokine receptors is 
emerging as major players in chemokine biology. We are 
just starting to understand the role of DARC in renal in-
flammation, and data on the other atypical chemokine 
receptors is slowly accumulating. Further studies on the 
functional role of these proteins might define them as 
therapeutic targets in renal inflammation.
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